Integrated Prostate Cancer Center Services

Integrated Prostate Cancer Program offers patients for whom standard treatments have failed a variety of options, which may alter the course of their disease while maintaining full quality of life. Within the context of multidisciplinary care and associated support services, the Integrated Prostate Cancer Program offers hope for patients with relapse of disease and for their families, as the investigations of new therapies continue.

At the present time, options include tumor vaccines, new chemotherapeutic agents, new combinations of standard chemotherapeutic agents, gene-modified immunotherapy, and in the near future anti-angiogenic agents. As the field of complementary medicine and our understanding of nutritional therapies advance, there should be additional opportunities for new interventions within this realm.

The specific disease states on which the Integrated Prostate Cancer Program focuses are patients with a rise in prostate specific antigen (PSA) following radical prostatectomy, patients with a rise in PSA following definitive radiation therapy, and patients with hormone refractory disease. Approaches to these disease states may involve variations of standard therapies, alone or in combination, or may entail new experimental strategies through clinical trials.